CCL5 and neoplasm: In prostate cancer, for instance, it has been indicated that the CCL5 produced by MSCs increases the expression of MMP9, an event that, on the one hand, could lead to tumor metastasis and, on the other hand, could attenuate the therapeutic efficacy of both chemotherapy and radiotherapy on tumor cells (70, 71).